Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
AssigneeAlexion Pharmaceuticals, Inc.
InventorsGiuseppe REMUZZI, Piero RUGGENENTI, Xiang GAO
Life of this patent
Estimating the term…
Abstract
Provided are methods for clinical treatment of Membranoproliferative glomerulonephritis (MPGN) by administering an anti-C5 antibody, or antigen binding fragment thereof.
Claims41
A method of treating an adult human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:
- 1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:
- 4, 5, and 6, respectively,
- wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 3.5 g in adults, and
- wherein the method comprises an administration cycle comprising (a) an induction phase followed by (b) a maintenance phase, wherein:
- (a) the induction phase comprises a period of four weeks, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered at a dose of 900 mg once per week;
- and
- (b) during the maintenance phase, the anti-C5 antibody, or antigen binding fragment thereof, is administered once at a dose of 1200 mg on the fifth week of the administration cycle, followed by 1200 mg every 14±2 days thereafter.
A method of treating a pediatric human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively,
- wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 40 mg/h/m2 (or exceeding 2 mg protein/mg creatinine in spot urine samples), and
- wherein the method comprises an administration cycle comprising (a) an induction phase followed by (b) a maintenance phase, wherein:
- (a) the anti-C5 antibody, or antigen binding fragment thereof, is administered during the induction phase at a dose of:
- 1. 900 mg once per week for four weeks to a ≥40 kg patient;
- 2. 600 mg once per week for two weeks to a 30 kg to <40 kg patient;
- 3. 600 mg once per week for two weeks to a 20 kg to <30 kg patient;
- 4. 600 mg once per week for one week to a 10 kg to <20 kg patient;
- 5. 300 mg once per week for one week to a 5 kg to <10 kg patient;
- and
- (b) the anti-C5 antibody, or antigen binding fragment thereof, is administered during the maintenance phase at a dose of:
- 1. 1200 mg on the fifth week of the administration cycle, followed by 1200 mg every two weeks thereafter, to a ≥40 kg patient;
- 2. 900 mg on the third week of the administration cycle, followed by 900 mg every two weeks thereafter, to a 30 kg to <40 kg patient;
- 3. 600 mg on the third week of the administration cycle, followed by 600 mg every two weeks thereafter, to a 20 kg to <30 kg patient;
- 4. 300 mg on the second week of the administration cycle, followed by 300 mg every two weeks thereafter, to a 10 kg to <20 kg patient;
- or
- 5. 300 mg on the second week of the administration cycle, followed by 300 mg every three weeks thereafter, to a 5 kg to <10 kg patient.
(canceled)
(canceled)
18-19. (canceled)
A method of treating an adult human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:19, 18, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively,
- wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 3.5 g, and
- wherein the method comprises an administration cycle and, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered:
- (a) once on Day 1 of the administration cycle at a dose of:
- 2400 mg to a patient weighing ≥40 to <60 kg, 2700 mg to a patient weighing ≥60 to <100 kg, or 3000 mg to a patient weighing ≥100 kg;
- and
- (b) on Day 15 of the administration cycle and every eight weeks thereafter at a dose of 3000 mg to a patient weighing ≥40 to <60 kg, 3300 mg to a patient weighing ≥60 to <100 kg, or 3600 mg to a patient weighing ≥100 kg.
26-28. (canceled)
31-34. (canceled)
(canceled)
39-40. (canceled)
42-43. (canceled)
(canceled)
Dependencies are inferred from the claim text.